Abstract:A skin‐penetrating peptide‐based peptide drone (PD) delivers the antitumoral but hepatotoxic protein, ConA, beyond the skin barrier, thereby exhibiting significantly superior antitumor (melanoma) efficacy to Aldara (imiquimod) cream. This transdermal strategy minimizes hepatic absorption of the proteins, resulting in negligible hepatotoxicity. Furthermore, the PD‐ConA complex avoids inducing the side effects associated with Aldara cream, including psoriasis‐like skin inflammation. Topical treatment offers a viable alternative for melanoma patients incompatible with surgical interventions. Herein, the study develops a skin‐penetrating peptide (SPP)‐based peptide drone (PD) for the transdermal delivery of antitumor proteins. To achieve cost‐effective therapeutics, Concanavalin A (ConA), which can be prepared through an extraction method, is loaded onto PDs. Compared with free proteins, ConA‐PD complexes (CPCs) demonstrate significantly greater skin permeation. Moreover, the CPCs exhibit potent anticancer activity both in vitro and in vivo, which substantially surpass the efficacy of the Aldara (imiquimod) cream. The CPC‐treated mouse skin remains clear, whereas Aldara cream induces side effects, including psoriasis‐like skin inflammation. The antimetastatic activity of the PD is identified as another advantage of CPC. The use of ConA as an anticancer agent has been significantly limited due to its high hepatotoxicity; however, the transdermal delivery strategy minimizes its hepatic absorption and, in turn, results in negligible hepatotoxicity. These results demonstrate the potential of the CPC as a novel therapeutic agent or an adjunct to other modalities for melanoma treatment, overcoming the limitations of existing materials while exhibiting superior efficacy.

Antineoplastic Drug‐Free Anticancer Strategy Enabled by Host‐Defense‐Peptides‐Mimicking Synthetic Polypeptides

Dual-vectors of Anti-Cancer Drugs and Genes Based on Ph-Sensitive Micelles Self-Assembled from Hybrid Polypeptide Copolymers

Heterochiral β-Peptide Polymers Combating Multidrug-Resistant Cancers Effectively without Inducing Drug Resistance

Anticancer Activities of Natural and Synthetic Peptides

Mimics of Host Defense Peptides Derived from Dendronized Polylysines for Antibacterial and Anticancer Therapy

Poly(l-Ornithine)-Based Polymeric Micelles as pH-Responsive Macromolecular Anticancer Agents

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Strategy to Enhance Anticancer Activity and Induced Immunogenic Cell Death of Antimicrobial Peptides by Using Non-Nature Amino Acid Substitutions

Rational design of a new short anticancer peptide with good potential for cancer treatment

A Self-Assembling Amphiphilic Peptide Dendrimer-Based Drug Delivery System for Cancer Therapy

Drug-free neutrally charged polypeptide nanoparticles as anticancer agents

Branched -helical peptides enhanced antitumor efficacy and selectivity

Recent advances in anticancer peptoids

DHPAC, a Novel Synthetic Microtubule Destabilizing Agent, Possess High Anti-Tumor Activity in Vincristine-Resistant Oral Epidermoid Carcinoma in Vitro and in Vivo

Peptide Drones Facilitating the Transdermal Delivery of Antitumor Proteins for Melanoma Treatment

Polymers with Distinctive Anticancer Mechanism That Kills MDR Cancer Cells and Inhibits Tumor Metastasis.

De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity

Data from Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem–Like Cells in Vivo

Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy

Histone Deacetylase‐Triggered Self‐Immolative Peptide‐Cytotoxins for Cancer‐Selective Drug Delivery

Attenuation Of Nontargeted Cell-Kill Using A High-Density Lipoprotein-Mimicking Peptide Phospholipid Nanoscaffold